Dr Neal discusses the design and outcomes of the CHRYSALIS study, investigating amivantamab for the treatment of EGFR exon 20-mutant advanced or metastatic lung cancer, and then briefly comments on a matched analysis of efficacy data on mobocertinib and amivantamab.
Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.
Mazyar Shadman, MD, MPH, explains how community oncologists can care for their patient after they have been treated with chimeric antigen receptor T cells.
Dr Terence Friedlander closes his discussion by highlighting ongoing clinicals in neoadjuvant MIBC treatment that excite him and speculates on how he would use immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant setting.
Terence Friedlander, MD, summarizes the remaining unmet needs for patients with MIBC.
Dr Terence Friedlander explains which adjuvant therapy he would have recommended for the patient with MIBC from the presented case.
Terence Friedlander, MD, continues his discussion of the CheckMate 247 trial by highlighting important updates from recent conferences on adjuvant nivolumab therapy in patients with MIBC.
Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.
Terence Friedlander, MD, reviews the available adjuvant therapy options for patients with stage II or III MIBC who previously underwent bladder removal surgery.
Dr Terence Friedlander defines cisplatin eligibility in patients with MIBC and discusses how many patients receive neoadjuvant cisplatin and the treatment approaches if a patient is ineligible.
Terence Friedlander, MD, presents the case of a 75-year-old patient with stage IIIA muscle-invasive bladder cancer (MIBC) for review, and explains how patients are risk-stratified.
Rana McKay, MD presents an overview of metastatic/stage IV RCC, touching on incidence, the typical RCC patient she sees in her practice, and available first-line treatments for metastatic clear cell RCC.
In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.
Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the findings from the ELAINE-1 trial.
Milind Javle, MD, discusses the use of durvalumab for locally advanced or metastatic biliary tract cancer.
Based on findings from the DESTINY-Gastric01 and -02 trials, the European Commission has approved fam-trastuzumab deruxtecan-nxki monotherapy for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Closing out his discussion on the management of advanced non–small cell lung cancer, an expert oncologist provides his hopes for future evolutions in the treatment paradigm.
In light of clinical data and real-world experience, Jason Porter, MD, considers how he would best select patients with non–small cell lung cancer for IO therapy.
Jason Porter, MD, shares a brief review of the toxicity profile noted on EMPOWER-Lung3 and provides practical advice on how to monitor for and manage adverse events.
Expert perspective on the EMPOWER-Lung3 clinical trial, which combined cemiplimab with chemotherapy as frontline treatment for patients with advanced NSCLC.
Comprehensive insight on the first-line treatment armamentarium available to patients diagnosed with metastatic squamous cell non–small cell lung cancer.
Centering discussion on a patient scenario of metastatic squamous cell NSCLC, expert oncologist Jason Porter, MD, shares his initial impressions on the case.
Brian Jonas, MS. PhD, discusses e-selection as a biomarker in acute myeloid leukemia, and how e-selectin inhibition works along with chemotherapy to decrease tumor growth.
Andreas Saltos, MD, discusses the key discoveries from a phase 1/1B trial of erlotinib and binimetinib in EGFR- and KRAS-mutated non–small cell lung cancer.
Melhem M. Solh, MD, discusses results of a study investigating allogeneic stem cell transplant in patients with myelodysplastic syndrome and acute myeloid leukemia with a TP53 mutation, previously presented at the 2022 Transplantation & Cellular Therapy Meetings.
Dr Joel Neal reviews data from the pivotal clinical trial leading to the FDA approval of mobocertinib for EGFR exon 20-mutated advanced or metastatic lung cancers.
Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.
Dr Piotrowska highlights the currently approved targeted therapies for EGFR exon 20 mutation-positive mNSCLC.
Robert J. Soiffer, MD, discusses the approaches to integrating chimeric antigen receptor T-cell therapy into the treatment of hematologic malignancies.
Dr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.